Effects on plasma noradrenaline may explain some of the improved insulin sensitivity seen by AT‐1 receptor blockade

References

• Elliott W. J., Meyer P. M. Incident diabetes in clinical trials of antihypertensive drugs: A network meta‐analysis. Lancet 2007; 369: 201–7
   PubMed Web of Science ®Google Scholar
• Hansson L., Lindholm L. H., Ekbom T., Dahlöf B., Lanke J., Schersten B., et al. Randomised trial of old and new antihypertensive drugs in elderly patients: Cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension‐2 study. Lancet 1999; 354: 751–1756
   PubMed Web of Science ®Google Scholar
• Major outcomes in high‐risk hypertensive patients randomized to angiotensin‐converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid‐Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981–97
   PubMed Web of Science ®Google Scholar
• Kjeldsen S. E., Julius S., Mancia G., McInnes G. T., Hua T., Weber M. A., et al. Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high‐risk hypertensive patients: The VALUE trial. J Hypertens 2006; 24: 1405–12
   PubMed Web of Science ®Google Scholar
• Julius S., Kjeldsen S. E., Weber M., Brunner H. R., Ekman S., Hansson L., et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial. Lancet 2004; 363: 2022–31
   PubMed Web of Science ®Google Scholar
• Padwal R., Laupacis A. Antihypertensive therapy and incidence of type 2 diabetes: A systematic review. Diabetes Care 2004; 27: 247–55
   PubMed Web of Science ®Google Scholar
• Aksnes T. A., Reims H. M., Guptha S., Moan A., Os I., Kjeldsen S. E. Improved insulin sensitivity with the angiotensin II‐receptor blocker losartan in patients with hypertension and other cardiovascular risk factors. J Hum Hypertens 2006; 20: 860–6
   PubMed Web of Science ®Google Scholar
• Aksnes T. A., Seljeflot I., Torjesen P. A., Höieggen A., Moan A., Kjeldsen S. E. Improved insulin sensitivity by the angiotensin II‐receptor blocker losartan is not explained by adipokines, inflammatory markers, or whole blood viscosity. Metabolism 2007; 56: 1470–7
   PubMed Web of Science ®Google Scholar
• Heart rate variability. Standards of measurement, physiological interpretation, and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Eur Heart J 1996; 7: 354–81
   Google Scholar
• La Rovere M. T., Mortara A., Schwartz P. J. Baroreflex sensitivity. J Cardiovasc Electrophysiol 1995; 6: 761–74
   PubMed Web of Science ®Google Scholar
• Peuler J. D., Johnson G. A. Simultaneous single isotope radioenzymatic assay of plasma norepinephrine, epinephrine and dopamine. Life Sci 1977; 21: 625–36
   PubMed Web of Science ®Google Scholar
• Kjeldsen S. E., Flaaten B., Eide I., Helgeland A., Leren P. Evidence of increased peripheral catecholamine release in patients with long‐standing, untreated essential hypertension. Scand J Clin Lab Invest 1982; 42: 217–23
   PubMed Web of Science ®Google Scholar
• Matthews D. R., Hosker J. P., Rudenski A. S., Naylor B. A., Treacher D. F., Turner R. C. Homeostasis model assessment: Insulin resistance and beta‐cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412–9
   PubMed Web of Science ®Google Scholar
• Moan A., Höieggen A., Seljeflot I., Risanger T., Arnesen H., Kjeldsen S. E. The effect of angiotensin II receptor antagonism with losartan on glucose metabolism and insulin sensitivity. J Hypertens 1996; 14: 1093–7
   PubMed Web of Science ®Google Scholar
• Julius S., Valentini M., Palatini P. Overweight and hypertension: A 2‐way street?. Hypertension 2000; 35: 807–13
   PubMed Web of Science ®Google Scholar
• Deibert D. C., DeFronzo R. A. Epinephrine‐induced insulin resistance in man. J Clin Invest 1980; 65: 717–21
   PubMed Web of Science ®Google Scholar
• Zeman R. J., Ludemann R., Easton T. G., Etlinger J. D. Slow to fast alterations in skeletal muscle fibers caused by clenbuterol, a beta 2‐receptor agonist. Am J Physiol 1988; 254: E726–E732
   PubMed Web of Science ®Google Scholar
• Brook R. D., Julius S. Autonomic imbalance, hypertension, and cardiovascular risk. Am J Hypertens 2000; 13: 112S–122S
   PubMed Web of Science ®Google Scholar
• Jamerson K. A., Julius S., Gudbrandsson T., Andersson O., Brant D. O. Reflex sympathetic activation induces acute insulin resistance in the human forearm. Hypertension 1993; 21: 618–23
   PubMed Web of Science ®Google Scholar
• Jamerson K. A., Smith S. D., Amerena J. V., Grant E., Julius S. Vasoconstriction with norepinephrine causes less forearm insulin resistance than a reflex sympathetic vasoconstriction. Hypertension 1994; 23: 1006–11
   PubMed Web of Science ®Google Scholar
• Palatini P., Julius S. Heart rate and the cardiovascular risk. J Hypertens 1997; 15: 3–17
   PubMed Web of Science ®Google Scholar
• Julius S., Gudbrandsson T., Jamerson K., Tariq S. S., Andersson O. The hemodynamic link between insulin resistance and hypertension. J Hypertens 1991; 9: 983–6
   PubMed Web of Science ®Google Scholar
• Lefrandt J. D., Heitmann J., Sevre K., Castellano M., Hausberg M., Fallon M., et al. The effects of dihydropyridine and phenylalkylamine calcium antagonist classes on autonomic function in hypertension: The VAMPHYRE study. Am J Hypertens 2001; 14: 1083–9
   PubMed Web of Science ®Google Scholar
• Struck J., Muck P., Trubger D., Handrock R., Weidinger G., Dendorfer A., et al. Effects of selective angiotensin II receptor blockade on sympathetic nerve activity in primary hypertensive subjects. J Hypertens 2002; 20: 1143–9
   PubMed Web of Science ®Google Scholar
• de Champlain J., Karas M., Nguyen P., Cartier P., Wistaff R., Toal C. B., et al. Different effects of nifedipine and amlodipine on circulating catecholamine levels in essential hypertensive patients. J Hypertens 1998; 16: 1357–69
   Web of Science ®Google Scholar
• Fogari R., Zoppi A., Corradi L., Preti P., Malalamani G. D., Mugellini A. Effects of different dihydropyridine calcium antagonists on plasma norepinephrine in essential hypertension. J Hypertens 2000; 18: 1871–5
   PubMed Web of Science ®Google Scholar
• Lopez L. M., Thorman A. D., Mehta J. L. Effects of amlodipine on blood pressure, heart rate, catecholamines, lipids and responses to adrenergic stimulus. Am J Cardiol 1990; 66: 1269–71
   PubMed Web of Science ®Google Scholar
• de Champlain J., Karas M., Assouline L., Nadeau R., LeBlanc A. R., Dube B., et al. Effects of valsartan or amlodipine alone or in combination on plasma catecholamine levels at rest and during standing in hypertensive patients. J Clin Hypertens 2007; 9: 168–78
   PubMedGoogle Scholar
• Grassi G. Renin–angiotensin‐sympathetic crosstalks in hypertension: Reappraising the relevance of peripheral interactions. J Hypertens 2001; 19: 1713–6
   PubMedGoogle Scholar
• Grassi G., Seravalle G., Dell'Oro R., Trevano F. Q., Bombelli M., Scopelliti F., et al. Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: Results of the CROSS study. J Hypertens 2003; 21: 1761–9
   PubMed Web of Science ®Google Scholar
• Fogari R., Derosa G., Zoppi A., Rinaldi A., Lazzari P., Fogari E., et al. Comparison of the effects of valsartan and felodipine on plasma leptin and insulin sensitivity in hypertensive obese patients. Hypertens Res 2005; 28: 209–14
   PubMed Web of Science ®Google Scholar
• Liao D., Carnethon M., Evans G. W., Cascio W. E., Heiss G. Lower heart rate variability is associated with the development of coronary heart disease in individuals with diabetes: The atherosclerosis risk in communities (ARIC) study. Diabetes 2002; 51: 3524–31
   PubMed Web of Science ®Google Scholar
• Aronson D. Pharmacologic modulation of autonomic tone: Implications for the diabetic patient. Diabetologia 1997; 40: 476–81
   PubMed Web of Science ®Google Scholar
• Flanagan D. E., Vaile J. C., Petley G. W., Moore V. M., Godsland I. F., Cockington R. A., et al. The autonomic control of heart rate and insulin resistance in young adults. J Clin Endocrinol Metab 1999; 84: 1263–7
   PubMedGoogle Scholar
• Lindmark S., Wiklund U., Bjerle P., Eriksson J. W. Does the autonomic nervous system play a role in the development of insulin resistance? A study on heart rate variability in first‐degree relatives of Type 2 diabetes patients and control subjects. Diabet Med 2003; 20: 399–405
   PubMedGoogle Scholar
• Pikkujamsa S. M., Huikuri H. V., Airaksinen K. E., Rantala A. O., Kauma H., Lilja M., et al. Heart rate variability and baroreflex sensitivity in hypertensive subjects with and without metabolic features of insulin resistance syndrome. Am J Hypertens 1998; 11: 523–31
   PubMed Web of Science ®Google Scholar
• Chern C. M., Hsu H. Y., Hu H. H., Chen Y. Y., Hsu L. C., Chao A. C. Effects of atenolol and losartan on baroreflex sensitivity and heart rate variability in uncomplicated essential hypertension. J Cardiovasc Pharmacol 2006; 47: 169–74
   PubMed Web of Science ®Google Scholar
• Javorka M., Javorkova J., Tonhajzerova I., Javorka K. Parasympathetic versus sympathetic control of the cardiovascular system in young patients with type 1 diabetes mellitus. Clin Physiol Funct Imaging 2005; 25: 270–4
   PubMedGoogle Scholar
• Grassi G., Vailati S., Bertinieri G., Seravalle G., Stella M. L., Dell'Oro R., et al. Heart rate as marker of sympathetic activity. J Hypertens 1998; 16: 1635–9
   PubMed Web of Science ®Google Scholar
• Kannel W. B., Kannel C., Paffenbarger R. S Jr., Cupples L. A. Heart rate and cardiovascular mortality: The Framingham Study. Am Heart J 1987; 113: 1489–94
   PubMed Web of Science ®Google Scholar
• Palatini P., Benetos A., Grassi G., Julius S., Kjeldsen S. E., Mancia G., et al. Identification and management of the hypertensive patient with elevated heart rate: Statement of a European Society of Hypertension Consensus Meeting. J Hypertens 2006; 24: 603–10
   PubMed Web of Science ®Google Scholar
• Mancia G., De B. G., Dominiczak A., Cifkova R., Fagard R., Germano G., et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105–87
   PubMed Web of Science ®Google Scholar
• Facchini F. S., Stoohs R. A., Reaven G. M. Enhanced sympathetic nervous system activity. The linchpin between insulin resistance, hyperinsulinemia, and heart rate. Am J Hypertens 1996; 9: 1013–7
   PubMed Web of Science ®Google Scholar
• Moan A., Nordby G., Rostrup M., Eide I., Kjeldsen S. E. Insulin sensitivity, sympathetic activity, and cardiovascular reactivity in young men. Am J Hypertens 1995; 8: 268–75
   PubMed Web of Science ®Google Scholar
• Reims H. M., Höieggen A., Fossum E., Rostrup M., Eide I., Kjeldsen S. E. Glucose disposal rates calculated from 60‐ to 90‐minute isoglycemic hyperinsulinemic glucose clamp correlate with cardiovascular risk factors in borderline hypertensive young men. Metabolism 2001; 50: 1175–80
   PubMedGoogle Scholar
• Kjeldsen S. E., Schork N. J., Leren P., Eide I. K. Arterial plasma norepinephrine correlates to blood pressure in middle‐aged men with sustained essential hypertension. Am Heart J 1989; 118: 775–81
   PubMed Web of Science ®Google Scholar
• Grassi G. Sympathetic deactivation as a goal of nonpharmacologic and pharmacologic antihypertensive treatment: Rationale and options. Curr Hypertens Rep 2003; 5: 277–80
   PubMed Web of Science ®Google Scholar
• Harsch I. A., Schahin S. P., Radespiel‐Troger M., Weintz O., Jahreiss H., Fuchs F. S., et al. Continuous positive airway pressure treatment rapidly improves insulin sensitivity in patients with obstructive sleep apnea syndrome. Am J Respir Crit Care Med 2004; 169: 156–62
   PubMed Web of Science ®Google Scholar
• Huggett R. J., Scott E. M., Gilbey S. G., Stoker J. B., Mackintosh A. F., Mary D. A. Impact of type 2 diabetes mellitus on sympathetic neural mechanisms in hypertension. Circulation 2003; 108: 3097–101
   PubMed Web of Science ®Google Scholar
• Grassi G., Seravalle G., Quarti‐Trevano F., Dell'Oro R., Bolla G., Mancia G. Effects of hypertension and obesity on the sympathetic activation of heart failure patients. Hypertension 2003; 42: 873–7
   PubMedGoogle Scholar
• Grassi G. Counteracting the sympathetic nervous system in essential hypertension. Curr Opin Nephrol Hypertens 2004; 13: 513–9
   PubMed Web of Science ®Google Scholar
• Taddei S., Virdis A., Mattei P., Duranti P., Favilla S., Salvetti A. Vascular renin–angiotensin system and sympathetic nervous system activity in human hypertension. J Cardiovasc Pharmacol 1994; 23(Suppl 1)S9–S14
   PubMedGoogle Scholar